Brensocatib 25 mg

Phase 3

Insmed Incorporated (INSM)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Non-Cystic Fibrosis Bronchiectasis

ARMPAP-PA02

Phase 2

View Full Landscape

Drug Information

Target Indication

Non-Cystic Fibrosis Bronchiectasis

Clinical Trial

NCT04594369

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/18/2025

Brinsupri

Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

PRIME

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

INSM

Insmed Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Treprostinil Palmitil Inhalation PowderPhase 3

Pulmonary Hypertension

LAI 590 mgPhase 3

NTM Lung Infection Due to MAC

Liposomal amikacin for inhalationPhase 3

Cystic Fibrosis

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.Phase 3

Pseudomonas Aeruginosa Infection

Treprostinil PalmitilPhase 3

Pulmonary Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts